Desensitization across the HLA barrier in kidney transplantaion

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 3, 2011, Pages 929-936

  Mohamed, Maha Abdalla ^a   Lorentzen, David ^a   Kim, Jim ^a   Djamali, Arjang ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Crossmatch; Desensitization; Intravenous Immunoglobulin; Kidney Transplantation; Plasmapheresis; Review; Rituximab; Splenectomy

Indexed keywords

BORTEZOMIB; CYTOMEGALOVIRUS ANTIBODY; HLA ANTIBODY; IMMUNOGLOBULIN; PLACEBO; RITUXIMAB; BORONIC ACID DERIVATIVE; HLA ANTIGEN; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE;

ACUTE GRAFT REJECTION; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ARTICLE; DESENSITIZATION; FLOW CYTOMETRY; GRAFT SURVIVAL; HEMODIALYSIS; HLA TYPING; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT MONITORING; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPLENECTOMY; SURVIVAL RATE; UNITED STATES; FEMALE; IMMUNOLOGY; MALE; METHODOLOGY; REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BORONIC ACIDS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; PLASMAPHERESIS; PYRAZINES; SENSITIVITY AND SPECIFICITY; SEX FACTORS; TREATMENT OUTCOME;

EID: 80053129473     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s197     Document Type: Article

References (65)

1. Herwig-Ulf Meier-Kriesche, Friedrich K Port, Akinlolu O Ojo, Steven M Rudich, Julie A Hanson, Diane M Cibrik, Alan B Leichtman and Bruce Kaplan: Effect of waiting time on renal transplant outcome: Kidney International 58, 1311-1317, (2000)
2. Vollmer, WM, Wahl, PW, Blagg, CR: Survival with dialysis and transplantation in patients with end-stage renal disease: N Engl J Med 308, 1553-1558, (1983) (Pubitemid 13056538)
3. Krakauer, H, Grauman, JS, McMullan, MR, Creede, CC: The recent U.S. experience in the treatment of end-stage renal disease by dialysis and transplantation: N Engl J Med 308, 1558-1563, (1983) (Pubitemid 13056539)
4. Wolfe, RA, Ashby, VB, Milford, EL, Ojo, AO, Ettenger, RE, Agodoa, LY, Held, PJ, Port, FK: Comparison ofmortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant: N Engl J Med 341,1725-1730, (1999)
5. J Michael Cecka, Raja Rajalingam, Jennifer Zhang, and Elaine F. Reed: Histocombatibility Testing, Crossmatching, and Immune Monitoring: Handbook of Kidney Transplantation, Fifth Edition, 36-60, (2010)
6. Stanley C. Jordan, and Mark D. Pescovitz. Presensitization: The Problem and Its Management: Clin J Am Soc Nephrol 1, 421-432, (2006)
7. Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik DM, Leichtman AB, Kaplan B: Effect of waiting time on renal transplant outcome: Kidney Int 58, 1311-1317, (2000)
8. Kaplan B, Schold J, Meier-Kriesche HU: Overview of large database analysis in renal transplantation: Am J Transplant 3, 1052-1056, (2003) (Pubitemid 37064543)
9. Organ Procurement Transplantation Network/Scientific Registry of Transplant Recipients: 2008 Annual Report: Transplant Data 1998-2007.
10. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; United Network for Organ Sharing: University Renal Research and Education Association (2008)
11. Ashley A. Vo., Alice Peng, Mieko Toyoda, Joseph Kahwaji, Kai Cao, Chih-Hung Lai, Nancy L. Reinsmoen3 Rafael Villicana, and Stanley C. Jordan1: Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation: Transplantation 89, 9, 1095-1102, (2010)
12. Organ Procurement Transplantation Network/Scientific Registry of Transplant Recipients. 2009. Available at: http://www.optn.org/data/. Accessed August 7, 2010.
13. United Network for Organ Sharing Data Base. Available at: http://www. unos.org.
14. Arun Gubta, Paul Sinnot: Clinical Relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a renal transplant, A risk factor: Human Immunology 70, 618-622, (2009)
15. Dusset H: Leukoagglutinins. IV. Leukoagglutinins and blood transfusion: Vox Sang 4, 190, (1954)
16. Patel R, Terasaki PI: Significance of the positive cross match test in kidney transplantation: N Engl J Med 280, 735-739, (1969)
17. Terasaki PI, McClelland JD: Microdroplet assay of human serum cytotoxins: Nature 204, 998-1000, (1964)
18. Susal C, Pelzel S, Simon T, Opelz G: Advances in preand post-transplant immunologic testing in kidney transplantation: Transplant Proc 2004; 36: 29-34. (Pubitemid 38177180)
19. Gebel H.M., Bray, R. M., Nickerson, P: Pre-Transplant Assessment of Donor-Reactive, HLA-Specific Antibodies in Renal Transplantation: Contraindication vs. Risk: American Journal of Transplantation 3, 1488-1500 (2003) (Pubitemid 37541506)
20. Zachary, A. A., Klingman, L., Thorne, N., Smerglia, A. R. & Teresi, G. A: variations of the lymphocytotoxicity test. An evaluation of sensitivity and specificity: Transplantation 60, 498-503, (1995)
21. James Gloor and Mark D. Stegall: Sensitized renal transplant recipients: current protocols and future directions: Nat Rev Nephrol 6, 297-306, (2010)
22. Bray, R. A: Flow cytometry in the transplant laboratory: Ann NY Acad Sci 677, 138-151, (1993) (Pubitemid 23161916)
23. Pei, R., Lee, J.-H., Shih, N.-J., Chen, M. & Terasaki, P. I: Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities: Transplantation 75, 43-49, (2003) (Pubitemid 36139693)
24. Pei, R., Lee, J.-H., Chen, T., Rojo, S. & Terasaki, P. I: Flow cytometric detection of HLA antibodies using a spectrum of microbeads: Hum Immunol 60, 1293-1302, (1999) (Pubitemid 30017514)
25. Andrea A. Zachary, Donna P. Lucas, Barbara Detrick, Mary S. Leffell: Naturally occurring interference in Luminex- assays for HLA-specific antibodies: Characteristics and resolution: Human Immunology 70, 496-501, (2009)
26. El-Awar, N., Lee, J. & Terasaki, P. I: HLA antibody identification with single antigen beads compared to conventional methods: Hum Immunol 66, 989-997, (2005) (Pubitemid 41790535)
27. Terasaki PI, Mottironi VD, Barnett EV: Cytotoxins in disease: Autocytotoxins in lupus: N Engl J Med 283, 724, (1970)
28. Guarnotta G, Triolo G: Immune complex-mediated inhibition of lymphocyte Fc-r receptors in plasma of patients with type 1 (insulin-dependent. diabetes mellitus: association with anti-ssDNA antibodies: Clin Immunol Immunopathol 54, 228, (1990)
29. Sumitran-Karuppan S, Moller E: The use of magnetic beads coated with soluble HLA class II proteins in antibody screening and for specificity determination of donor reactive antibodies: Transplantation 61, 1539, (1996)
30. Pei R, Wang G, Tarsitani C, Rojo S, Chen T, Takemura S, Liu A, Lee JH: Simultaneous HLA class I and class II antibodies screening with flow cytometry: Hum Immunol 59, 313, (1998)
31. Arun Gubta and Paul Sinnott: Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: risk factor: Human Immunology 70, 618-622, (2009)
32. Zachary AA, Leffell MS: Detecting and monitoring human leukocyte antigen specific antibodies: Human Immunol 69, 591-604, (2008)
33. James Gloor and Mark D. Stegall: Sensitized renal transplant recipients: current protocols and future directions: Nat Rev Nephrol 6, 297-306, (2010)
34. Koch, C. A., Khalpey, Z. I. & Platt, J. L: Accommodation: preventing injury in transplantation and disease: J Immunol 172, 5143-5148, (2004) (Pubitemid 38542008)
35. Salama AD, Delikouras A, Pusey CD, Cook HT, Bhangal G, Lechler RI, Dorling A: Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody: Am J Transplant 1, 260-269, (2001) (Pubitemid 33674170)
36. Robert A. Montgomery and Andrea A. Zachary: Transplanting patients with a positive donor-specific crossmatch: A single center's perspective: Pediatr Transplantation 8, 535-542, (2004) (Pubitemid 40052349)
37. Biggs R: Splenectomy and Renal Transplantation: British medical journal 4, 247, (1974)
38. Opelz, G., and Terasaki, P. I: Role of splenectomy in renal Transplantation: Transplantation 15, 605, (1973)
39. Kauffman, H. M., et al: Splenectomy and renal transplantation: Surgery, Gynecology, and Obstetrics 193, 33, (1974)
40. Tyden G, Kumlien G, Fehrman I: Successful ABOincompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab: Transplantation 76, 730-731, (2003) (Pubitemid 37072012)
41. Locke JE, Zachary AA, Haas M et al: The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 7, 842-846, (2007) (Pubitemid 46481192)
42. Michel D. Kazatchkine, MD, and Srini V. K Averi, D.V.M., PhD: Immunomodulation of autoimmune and inflammatory diseases with intravenous immuno globulin: N Engl J Med 345, 10, 747-755, (2001)
43. Nicole A. Weimert and Rita R. Alloway: Renal Transplantation in High-Risk Patients: Drugs 67 (11), 1603-1627, (2007) (Pubitemid 47267299)
44. Jordan, S. C., Toyoda, M. & VO, A. A: Intravenous immunoglobulin a natural regulator of immunity and inflammation: Transplantation 88, 1-6, (2008)
45. Rossi, F., Dietrich, G. & Kazatchkine, M. D: Antiidiotypic suppression of autoantibodies with normal polyspecific immunoglobulins: Res Immunol 140, 19-31, (1989) (Pubitemid 19121896)
46. Stanley C. Jordan, M.D., and (by invitation. Ashley Vo, Pharm D., Dolly Tyan PhD, and Mieko Toyota, PhD: Desensitization therapy with intravenous gammaglobulin (IVIG): Applications on solid organ transplantation: Transactions of the American clinical and climatological association 117, 199-211, (2006)
47. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial: J Am Soc Nephrol 15, 3256-3262, (2004) (Pubitemid 39578859)
48. R. A. Montgomery: Renal Transplantation Across HLA and ABO Antibody Barriers: Integrating Paired Donation into Desensitization Protocols: American Journal of Transplantation 10, 449-457, (2010)
49. S. C. Jordana,b, A. A. Voa, A. Penga, M. Toyodab and D. Tyanc: Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients. American Journal of Transplantation 6, 459-466, (2006)
50. J. H. M. Beimier, C. Susal and M. Zeier: Desensitization strategies enabling successful renal transplantation in highly sensitized patients: Clin Transplant 20, (suppl. 17), 7-12, (2006) (Pubitemid 44697895)
51. Lorenz M, Regele H, Schillinger M, Kletzmayr J, Haidbauer B, Derfler K, Druml W, Bohmig GA: Peritranslant immunoadsorption: a strategy enabling transplantation in highly sensitized cross-match positive cadaveric kidney allograft recipients: Transplantation 79, 696, (2005)
52. Montgomery RA, Zachary AA, Racusen LC: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients: Transplantation 70, 887-895, (2000)
53. Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S: Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center' s experience: Transplantation 86, 96-103, (2008)
54. Haririan A, Nogueira J, Kukuruga D, Schweitzer E, Hess J, Gurk-Turner C, Jacobs S, Drachenberg C, Bartlett S, Cooper M: Positive cross-match living donor kidney transplantation: longer-term outcomes: Am J Transplant 9, 536-542, (2009)
55. Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, Kaplan B, Benedetti E, Oberholzer J: Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience: Transplantation 87, 268-273, (2009)
56. Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, Roggero AL, Fineberg NS, Taber T, Kraus MA, Pescovitz MD: Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: safety, pharmacodynamics, and pharmacokinetics: Transplantation 77, 542-8, (2004) (Pubitemid 38282809)
57. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin: N Engl J Med 355, 1772-9, (2006) (Pubitemid 44631360)
58. Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A, Ribes D, Cointault O, Lavayssière L, Guitard J, Durand D, Rostaing L: Rituximab therapy for acute humoral rejection after kidney transplantation: Transplantation 83, 1277-80, (2007) (Pubitemid 46743692)
59. Salama AD, Pusey CD: Drug insight: rituximab in renal disease in transplantation: Nat Clin Pract Nephrol 2, 221-30, (2006) (Pubitemid 43787288)
60. Ashley A. Vo, Pharm.D., Marina Lukovsky, Pharm.D., Mieko Toyoda, Ph.D., Jennifer Wang, M.D., Nancy L. Reinsmoen, Ph.D., Chih-Hung Lai, Ph.D., Alice Peng, M.D., Rafael Villicana, M.D., and Stanley C. Jordan, M.D: Rituximab and intravenous immune globulin for desensitization during renal transplantation: N Engl J Med 3593), 242-251, (2008) (Pubitemid 352008439)
61. Rajkumar, S. v., Richardson, P. G., Hideshima, T. and Anderson, K. C: Proteasome inhibition as a novel therapeutic target in human cancer: J Clin Oncol 23, 630-639 (2005) (Pubitemid 46224241)
62. Kyle, R. A. and Rajkumar, S. v: Multiple myeloma: N Engl J Med 351, 1860-1873 (2004)
63. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD: Proteosome inhibition causes apoptosis of normal human plasma cells preventing antibody production: Am J Transplant 9, 201-209, (2009)
64. Diwan T, Burns J, Perry D. et al: Effect of proteasome inhibition on alloantibody secreting cells in vivo: Am J Transplant 9 (Suppl. 2), 241 (2009)
65. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES: Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection: Transplantation 86, 1754-1761 (2008)